CN103524560A - 伏立康磷酸酯钠水合物及其多晶型 - Google Patents
伏立康磷酸酯钠水合物及其多晶型 Download PDFInfo
- Publication number
- CN103524560A CN103524560A CN201310449024.0A CN201310449024A CN103524560A CN 103524560 A CN103524560 A CN 103524560A CN 201310449024 A CN201310449024 A CN 201310449024A CN 103524560 A CN103524560 A CN 103524560A
- Authority
- CN
- China
- Prior art keywords
- ester sodium
- phosphate ester
- sodium hydrate
- voriconazole
- voriconazole phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004740 voriconazole Drugs 0.000 title claims abstract description 105
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 title claims abstract description 94
- JCVGSKJSMKEPAM-UHFFFAOYSA-J tetrasodium;phosphonato phosphate;hydrate Chemical compound O.[Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O JCVGSKJSMKEPAM-UHFFFAOYSA-J 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 claims abstract description 39
- 239000013078 crystal Substances 0.000 claims abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 claims abstract description 8
- 206010017533 Fungal infection Diseases 0.000 claims abstract description 5
- 208000031888 Mycoses Diseases 0.000 claims abstract description 5
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims abstract 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 129
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 80
- 229910019142 PO4 Inorganic materials 0.000 claims description 78
- 239000010452 phosphate Substances 0.000 claims description 78
- 150000002148 esters Chemical class 0.000 claims description 74
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 74
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 27
- 239000011734 sodium Substances 0.000 claims description 27
- 229910052708 sodium Inorganic materials 0.000 claims description 27
- 239000007787 solid Substances 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 21
- 238000002425 crystallisation Methods 0.000 claims description 20
- 230000008025 crystallization Effects 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 238000001228 spectrum Methods 0.000 claims description 4
- 230000000843 anti-fungal effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000010792 warming Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims 3
- 229940124447 delivery agent Drugs 0.000 claims 2
- 238000012377 drug delivery Methods 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 150000002576 ketones Chemical class 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- TWHXWYVOWJCXSI-UHFFFAOYSA-N phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O TWHXWYVOWJCXSI-UHFFFAOYSA-N 0.000 abstract description 8
- 235000019441 ethanol Nutrition 0.000 abstract 1
- -1 phosphoric acid ester sodium hydrate Chemical class 0.000 description 42
- 238000004090 dissolution Methods 0.000 description 20
- 238000001035 drying Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- 241000222122 Candida albicans Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002798 polar solvent Substances 0.000 description 4
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241001225321 Aspergillus fumigatus Species 0.000 description 3
- 229940091771 aspergillus fumigatus Drugs 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000002447 crystallographic data Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 201000002909 Aspergillosis Diseases 0.000 description 2
- 208000036641 Aspergillus infections Diseases 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- HUHUEKUVYQUFBW-DDTHSEKNSA-N ClC1(O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO.[Na] Chemical compound ClC1(O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO.[Na] HUHUEKUVYQUFBW-DDTHSEKNSA-N 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 241000132889 Scedosporium Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical group [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000011082 depyrogenation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002642 intravenous therapy Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000008965 mitochondrial swelling Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
样品 时间 | 0小时(杂质%) | 24小时(杂质%) |
伏立康唑磷酸盐水合物 | 单杂0.06%总杂0.09% | 单杂0.08%总杂0.13% |
伏立康唑磷酸盐无水合物 | 单杂0.07%总杂0.10% | 单杂0.30%总杂0.37% |
Claims (14)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310449024.0A CN103524560A (zh) | 2013-09-28 | 2013-09-28 | 伏立康磷酸酯钠水合物及其多晶型 |
PCT/CN2014/087195 WO2015043453A1 (zh) | 2013-09-28 | 2014-09-23 | 伏立康磷酸酯钠水合物及其多晶型 |
US14/917,133 US9650400B2 (en) | 2013-09-28 | 2014-09-23 | Voriconazole sodium phosphate hydrates and polymorphs thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310449024.0A CN103524560A (zh) | 2013-09-28 | 2013-09-28 | 伏立康磷酸酯钠水合物及其多晶型 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103524560A true CN103524560A (zh) | 2014-01-22 |
Family
ID=49926955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310449024.0A Pending CN103524560A (zh) | 2013-09-28 | 2013-09-28 | 伏立康磷酸酯钠水合物及其多晶型 |
Country Status (3)
Country | Link |
---|---|
US (1) | US9650400B2 (zh) |
CN (1) | CN103524560A (zh) |
WO (1) | WO2015043453A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015043453A1 (zh) * | 2013-09-28 | 2015-04-02 | 陕西合成药业股份有限公司 | 伏立康磷酸酯钠水合物及其多晶型 |
CN107468656A (zh) * | 2016-06-08 | 2017-12-15 | 陕西合成药业股份有限公司 | 包含伏立康唑磷酸酯或其药用盐的药物组合物 |
CN107652325A (zh) * | 2016-07-25 | 2018-02-02 | 天地人和生物科技有限公司 | 伏立康唑磷酸酯二钠的无定型晶型及其制备方法 |
CN108084163A (zh) * | 2018-01-23 | 2018-05-29 | 珠海润都制药股份有限公司 | 一种制备小粒径伏立康唑的方法 |
CN111700864A (zh) * | 2020-06-28 | 2020-09-25 | 海南倍特药业有限公司 | 一种注射用伏立康唑的制备方法 |
CN115536560A (zh) * | 2022-08-05 | 2022-12-30 | 上海万巷制药有限公司 | 一种二巯丙磺钠一水合物的制备方法、胶囊及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1210540A (zh) * | 1996-02-02 | 1999-03-10 | 辉瑞研究开发公司 | 用于治疗的三唑衍生物 |
CN101723980A (zh) * | 2009-12-04 | 2010-06-09 | 陕西合成药业有限公司 | 用于治疗的三唑衍生物 |
CN101744778A (zh) * | 2010-02-01 | 2010-06-23 | 陕西合成药业有限公司 | 一种注射用伏立康唑磷酸酯及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101824002B (zh) | 2010-05-13 | 2012-01-11 | 南京华威医药科技开发有限公司 | 水溶性三唑类化合物及其合成方法 |
CN103304600B (zh) * | 2013-03-04 | 2018-05-25 | 陕西合成药业股份有限公司 | 一种伏立康唑磷酸酯三水合物及其制备方法和用途 |
CN103524560A (zh) * | 2013-09-28 | 2014-01-22 | 陕西合成药业有限公司 | 伏立康磷酸酯钠水合物及其多晶型 |
-
2013
- 2013-09-28 CN CN201310449024.0A patent/CN103524560A/zh active Pending
-
2014
- 2014-09-23 US US14/917,133 patent/US9650400B2/en active Active
- 2014-09-23 WO PCT/CN2014/087195 patent/WO2015043453A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1210540A (zh) * | 1996-02-02 | 1999-03-10 | 辉瑞研究开发公司 | 用于治疗的三唑衍生物 |
CN101723980A (zh) * | 2009-12-04 | 2010-06-09 | 陕西合成药业有限公司 | 用于治疗的三唑衍生物 |
CN101744778A (zh) * | 2010-02-01 | 2010-06-23 | 陕西合成药业有限公司 | 一种注射用伏立康唑磷酸酯及其制备方法 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015043453A1 (zh) * | 2013-09-28 | 2015-04-02 | 陕西合成药业股份有限公司 | 伏立康磷酸酯钠水合物及其多晶型 |
US9650400B2 (en) | 2013-09-28 | 2017-05-16 | Shaanxi Synthetic Pharmaceutical Co., Ltd. | Voriconazole sodium phosphate hydrates and polymorphs thereof |
CN107468656A (zh) * | 2016-06-08 | 2017-12-15 | 陕西合成药业股份有限公司 | 包含伏立康唑磷酸酯或其药用盐的药物组合物 |
CN107652325A (zh) * | 2016-07-25 | 2018-02-02 | 天地人和生物科技有限公司 | 伏立康唑磷酸酯二钠的无定型晶型及其制备方法 |
CN108084163A (zh) * | 2018-01-23 | 2018-05-29 | 珠海润都制药股份有限公司 | 一种制备小粒径伏立康唑的方法 |
CN108084163B (zh) * | 2018-01-23 | 2019-01-15 | 珠海润都制药股份有限公司 | 一种制备小粒径伏立康唑的方法 |
CN111700864A (zh) * | 2020-06-28 | 2020-09-25 | 海南倍特药业有限公司 | 一种注射用伏立康唑的制备方法 |
CN115536560A (zh) * | 2022-08-05 | 2022-12-30 | 上海万巷制药有限公司 | 一种二巯丙磺钠一水合物的制备方法、胶囊及其应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2015043453A1 (zh) | 2015-04-02 |
US9650400B2 (en) | 2017-05-16 |
US20160215008A1 (en) | 2016-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103524560A (zh) | 伏立康磷酸酯钠水合物及其多晶型 | |
US20080177083A1 (en) | Use of Levo-Ornidazole For Preparing Anti-Parasitic Infection Drug | |
CN1847243A (zh) | 一种新的伏立康唑可溶性盐的制备方法及其制剂 | |
CN101723980A (zh) | 用于治疗的三唑衍生物 | |
CN101817834B (zh) | 一类吡唑的衍生物、其制备方法和用途 | |
CN112778369B (zh) | 一种三唑类衍生物及其制备方法和用途 | |
RU2497521C1 (ru) | Фармацевтическая композиция, обладающая противогрибковой активностью, и способ ее получения | |
CN107365272A (zh) | 一种新型咪唑类化合物及其制备方法和在医学上的应用 | |
CN102697740B (zh) | 一种注射用盐酸吉西他滨冻干粉及其制备方法 | |
CN103304600B (zh) | 一种伏立康唑磷酸酯三水合物及其制备方法和用途 | |
CN101302201A (zh) | 用于治疗的硝基咪唑衍生物 | |
EP3770165B1 (en) | Posaconazole phosphate ester mono choline salt, preparation method therefor and use thereof | |
EP3204120B1 (en) | Methods and compositions for increasing the potency of antifungal agents | |
CN115192524A (zh) | 一种包载链状难溶药物的聚合型胶束及制备方法和应用 | |
CN112999164A (zh) | 一种伏立康唑干混悬剂及其制备方法 | |
CN101323601A (zh) | 用于治疗的三唑衍生物 | |
CN102002054B (zh) | 一种吡唑类化合物及其制备方法和用途 | |
CN100421672C (zh) | 抗肿瘤的复方香菇多糖制剂及其制备方法 | |
CN103585119A (zh) | 一种包含依前列醇及其药用盐的稳定化制剂及其制备方法 | |
CN100386089C (zh) | 一种复方香菇多糖制剂及其制备方法 | |
CN102503954B (zh) | 咪唑衍生物、其制备方法和用途 | |
CN102949350A (zh) | 一种替莫唑胺的冻干制剂及其制备方法 | |
CN107652325A (zh) | 伏立康唑磷酸酯二钠的无定型晶型及其制备方法 | |
CN103145732B (zh) | 一类哌嗪的抗真菌衍生物、其制备方法和用途 | |
CN110563642A (zh) | 抗真菌化合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 710075 Shaanxi city of Xi'an province high tech Zone Three New Road No. 2 building 30803 commercial sea cloud chamber Applicant after: Shaanxi Hecheng Pharmaceutical Co., Ltd. Address before: 710075 Shaanxi city of Xi'an province high three road No. 2 Haijia Genting C building room 803 Applicant before: Shaanxi Synthetic Pharmaceutical Co, Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHAANXI SYNTHETIC PHARMACEUTICAL CO., LTD. TO: SHAANXI HECHENG PHARMACEUTICAL CO., LTD. |
|
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140122 |